VBIO · Valion Bio, Inc.
$0.12
0.00 (-3.83%)
At close · Aug 28
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on the Company’s current cash levels and burn rate, amongst other things, the Company believes its cash and financial resources may be insufficient to meet the Company’s anticipated needs for the twelve months following the date of issuance of the financial statements for the six months ended June 30, 2026, included elsewhere in this Report, which raises substantial doubt about the Company’s ability to continue as a going concern within one year from the issuance date of the financial statements.”View the 10-Q filed Aug 14, 2026
Market Cap
$2.68M
Shares
22.19M
Valion Bio, Inc. Earnings Call Transcripts
Quarterly earnings calls for Valion Bio, Inc. (VBIO), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲32.5%
$428,000
−$2.24M
'22 Q1
22-05-16
▲97%
$528,000
−$3.02M
'22 Q2
22-08-15
▲72.2%
$477,000
−$2.58M
'22 Q3
22-11-14
▲4.6%
$407,000
−$2.25M
'22 Q4
23-03-31
▼12.1%
$376,000
−$2.12M
'23 Q1
23-05-15
▼69.5%
$161,000
−$2.12M
'23 Q2
23-08-14
▼40.9%
$282,000
−$1.76M
'23 Q3
23-11-14
▼12.3%
$357,000
−$2.24M
'23 Q4
24-03-25
▼13%
$140,000
−$1.27M
'24 Q2
24-08-14
▼55.3%
$126,000
−$1.43M
'24 Q3
24-11-14
▼49.6%
$180,000
−$1.48M
'24 Q4
25-03-21
▼79%
$70,000
−$1.50M
'25 Q1
25-05-15
▼38.6%
$86,000
−$1.93M
'25 Q2
25-08-14
LATEST
▲15.9%
$146,000
−$2.60M
'25 Q3
25-11-14
Earnings call
FY26 · Q1
2026-05-14
Valion Bio, Inc. (VBIO) Q1 2026 Earnings Call Transcript
Confident tone
Velocity Bioworks biomanufacturing / CDMO
Intolamid (Entolamod) TLR5 agonist asset
Corporate rebranding and governance
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-25
Valion Bio, Inc. (VBIO) Q4 2025 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-14
Valion Bio, Inc. (VBIO) Q3 2025 Earnings Call Transcript
Confident tone
Entolimod for acute radiation syndrome (ARS)
Strategic transformation to biopharmaceuticals
VNS (vagus nerve stimulation) program
Revenue
$146,000
▲ 15.9% YoY Gross margin
-99.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
Valion Bio, Inc. (VBIO) Q2 2025 Earnings Call Transcript
Confident tone
Entolimod for Acute Radiation Syndrome (ARS)
Government/defense stockpile opportunity
Consumer Health Tech (ClearUP) wind-down
Revenue
$86,000
▼ 38.6% YoY Diluted EPS
$-2.19
Gross margin
62.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-15
Valion Bio, Inc. (VBIO) Q1 2025 Earnings Call Transcript
Confident tone
Entolimod licensing and TLR5 program
Government / agency relationships and funding
Non-invasive vagus nerve stimulation (VNS) program
Revenue
$70,000
▼ 79% YoY Diluted EPS
$-2.52
Gross margin
71.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-21
Valion Bio, Inc. (VBIO) Q4 2024 Earnings Call
Revenue
$180,000*
▼ 49.6% YoY Gross margin
-132.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-14
Valion Bio, Inc. (VBIO) Q3 2024 Earnings Call Transcript
Positive tone
Vagus nerve stimulation (VNS) program
ClearUP product line turnaround
Capital raising strategy
Revenue
$126,000
▼ 55.3% YoY Diluted EPS
$-3.91
Gross margin
34.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Valion Bio, Inc. (VBIO) Q2 2024 Earnings Call Transcript
Positive tone
VNS program / clinical results
ClearUP product line
Intellectual property and patents
Revenue
$140,000
▼ 13% YoY Diluted EPS
$-5.37
Gross margin
21.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-25
Valion Bio, Inc. (VBIO) Q4 2023 Earnings Call Transcript
Positive tone
Vagus nerve stimulation (VNS) research
Gross profit and margin improvement
Distribution partnerships
Revenue
$357,000*
▼ 12.3% YoY Gross margin
1.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-14
Valion Bio, Inc. (VBIO) Q3 2023 Earnings Call Transcript
Revenue
$282,000
▼ 40.9% YoY Diluted EPS
$-25.16
Gross margin
38.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-14
Valion Bio, Inc. (VBIO) Q2 2023 Earnings Call Transcript
Revenue
$161,000
▼ 69.5% YoY Diluted EPS
$-121.72
Gross margin
37.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-15
Valion Bio, Inc. (VBIO) Q1 2023 Earnings Call
Revenue
$376,000
▼ 12.1% YoY Diluted EPS
$-178.84
Gross margin
30.1%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-31
Valion Bio, Inc. (VBIO) Q4 2022 Earnings Call
Revenue
$407,000*
▲ 4.6% YoY Gross margin
10.1%
Rev · 6q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Valion Bio, Inc. (VBIO) Q3 2022 Earnings Call
Revenue
$477,000
▲ 72.2% YoY Diluted EPS
$-459.00
Gross margin
13.2%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-15
Valion Bio, Inc. (VBIO) Q2 2022 Earnings Call
Revenue
$528,000
▲ 97% YoY Diluted EPS
$-544.00
Gross margin
23.7%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-16
Valion Bio, Inc. (VBIO) Q1 2022 Earnings Call
Revenue
$428,000
▲ 32.5% YoY Diluted EPS
$-391.00
Gross margin
16.4%
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Showing 1–16 of 16 earnings calls